Candel Therapeutics, Inc.

NASDAQ:CADL

Biotechnology

Healthcare
$5.32 +0.56%

+$0.05 today

Market cap
$417.33M
Beta
-0.48
P/E (TTM)
-9.2
EPS (TTM)
-$0.87
52W Low $4.35High $9.57

Volume 1.39M

Average 1.82M

CADL Debt Repayment

Cash used to repay borrowings during the period.

Candel Therapeutics, Inc.NASDAQ: CADL

Debt Repayment · Q1 FY2026 · quarter ended Mar 2026

Debt repayment turns positive

Q1 FY2026 debt repayment was $0, compared with -$2.5M a year earlier. Trailing-twelve-month debt repayment was $2.5M. Over 3 fiscal years it compounded at +22.1% a year.

Context

  • Debt repayment increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly debt repayment holds near $0 or moves back toward the trailing-twelve-month quarterly average of $625K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$36.21M+495.0% YoY
LTMMar 2026
$2.5M+125.0% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+100.0%——
1 year+495.0%——
3-year CAGR+22.1%——
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
36.21M USD
Year-over-year change
+495.0%

Debt Repayment vs competitors

How CADL compares with its peers on the latest reported figures

  • Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +125.0% is the highest of 2, against a peer median of +0.0%.
CADL Competitors
Debt Repayment for CADL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PBYIPuma Biotechnology, Inc.LTM Mar 2026$44.44M USD+0.0%—19.6%
CADLCandel Therapeutics, Inc.LTM Mar 2026$2.5M USD+125.0%+22.1%—
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$0 USD——0.0%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$0 USD——0.0%
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$0 USD———
IMMXImmix Biopharma, Inc.LTM Mar 2026$0 USD———
IPSCCentury Therapeutics, Inc.LTM Mar 2026$0 USD———
MGNXMacroGenics, Inc.LTM Mar 2026$0 USD——0.0%
GNLXGenelux CorporationLTM Mar 2026$0 USD——0.0%
NBPNovaBridge BiosciencesLTM Sep 2025CN¥0 CNY———
Peer median (excluding CADL) —+0.0%—0.0%

Competitors are the stored peer set for CADL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(36.12M)(18.79M)(37.94M)(55.18M)(38.18M)
Depreciation & Amortization232K778K1.28M990K845K
Deferred Income Tax11.51M0000
Stock-Based Compensation2.96M2.31M3.09M5.31M3.82M
Change in Working Capital(876K)71K(378K)346K2.19M
Accounts Receivables00000
Inventory00000
Accounts Payables669K(1.21M)45K(185K)802K
Other Working Capital(1.55M)1.28M(378K)531K1.39M
Other Non-Cash Items76K(15.78M)(301K)21.51M(6.98M)
Operating Cash Flow(22.22M)(31.42M)(34.24M)(27.02M)(38.31M)
Capital Expenditures(1.84M)(1.3M)(457K)(16K)(587K)
Acquisitions (Net)000027K
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00177K00
Investing Cash Flow(1.84M)(1.3M)(280K)(16K)(560K)
Debt Repayment019.91M0(9.17M)36.21M
Common Stock Issued71.34M00101.76M19.89M
Common Stock Repurchased00(121K)00
Dividends Paid00000
Other Financing Activities465K64K01.69M0
Financing Cash Flow71.8M19.97M(121K)94.28M56.1M
Effect of Forex Changes00000
Net Change in Cash47.75M(12.74M)(34.65M)67.24M17.23M
Free Cash Flow(24.05M)(32.72M)(34.7M)(27.04M)(38.9M)

Candel Therapeutics, Inc.

NASDAQ:CADL

Intrinsic Alpha fair value

Locked

Current Price

$5.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.